Research Paper
BMC: MicroRNA expression distinguishes SCLC from NSCLC lung tumor cells and suggests a possible pathological relationship between SCLCs and NSCLCs
June 17, 2010
Liqin Du, Jeoffrey J Schageman, Irnov, Luc Girard, Scott M Hammond, John D Minna, Adi F Gazdar & Alexander Pertsemlidis Abstract Background Recent studies have shown that microRNAs (miRNAs) play roles in tumorigenesis and are reliable classifiers of certain cancer types and subtypes. However, the role of miRNAs in the pathogenesis and diagnosis of small cell […]
BMC Systems Biology: Building and analyzing protein interactome networks by cross-species comparisons
March 30, 2010
Amy M Wiles, Mark Doderer, Jianhua Ruan, Ting-Ting Gu, Dashnamoorthy Ravi, Barron Blackman & Alexander JR Bishop Abstract Background A genomic catalog of protein-protein interactions is a rich source of information, particularly for exploring the relationships between proteins. Numerous systems-wide and small-scale experiments have been conducted to identify interactions; however, our knowledge of all interactions for any one species is incomplete, and […]
Breast Cancer Research Treatment: Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers
February 24, 2010
Susan M Domchek 1, Tara M Friebel, Judy E Garber, Claudine Isaacs, Ellen Matloff, Rosalind Eeles, D Gareth Evans, Wendy Rubinstein, Christian F Singer, Stephen Rubin, Henry T Lynch, Mary B Daly, Jeffrey Weitzel, Patricia A Ganz, Gabriella Pichert, Olufunmilayo I Olopade, Gail Tomlinson, Nadine Tung, Joanne L Blum, Fergus Couch, Timothy R Rebbeck Abstract Risk-reducing salpingo-oophorectomy (RRSO) is widely used for cancer risk reduction in BRCA1 or BRCA2 (BRCA1/2) mutation carriers. Occult ovarian/fallopian tube cancers […]
Pediatric Blood & Cancer: Establishment and characterization of a cancer cell line derived from an aggressive childhood liver tumor
December 1, 2009
Tina T-L Chen 1, Dinesh Rakheja, Jaclyn Y Hung, Peter J Hornsby, Piotr Tabaczewski, Marcio Malogolowkin, James Feusner, Frank Miskevich, Roger Schultz, Gail E Tomlinson Abstract Background: Hepatoblastoma is a rare malignancy of childhood. The scarcity of adequate cell models has limited our understanding of this tumor. Here we describe and characterize a new human liver tumor cell line, Hep293TT, derived from an aggressive childhood hepatoblastoma. […]
Breast Cancer Research Treatment: Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers
November 18, 2009
Amanda B Spurdle 1, Paul Fahey, Xiaoqing Chen, Lesley McGuffog, kConFab; Douglas Easton, Susan Peock, Margaret Cook, EMBRACE; Jacques Simard, INHERIT; Tim R Rebbeck, MAGIC; Antonis C Antoniou, Georgia Chenevix-Trench Abstract The GSTP1, GSTM1, and GSTT1 detoxification genes all have functional polymorphisms that are common in the general population. A single study of 320 BRCA1/2 carriers previously assessed their effect in BRCA1 or BRCA2 mutation carriers. This study showed no […]
BMC Research: Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers
October 20, 2009
Susan L Neuhausen 1, Sean Brummel, Yuan Chun Ding, Christian F Singer, Georg Pfeiler, Henry T Lynch, Katherine L Nathanson, Timothy R Rebbeck, Judy E Garber, Fergus Couch, Jeffrey Weitzel, Steven A Narod, Patricia A Ganz, Mary B Daly, Andrew K Godwin, Claudine Isaacs, Olufunmilayo I Olopade, Gail Tomlinson, Wendy S Rubinstein, Nadine Tung, Joanne L Blum, Daniel L Gillen Abstract Introduction: Women who carry mutations in BRCA1 and BRCA2 have a substantially increased risk of developing breast […]
PLOS Genetics: A Network of Conserved Damage Survival Pathways Revealed by a Genomic RNAi Screen
October 19, 2009
Dashnamoorthy Ravi, Amy M. Wiles, Selvaraj Bhavani, Jianhua Ruan, Philip Leder, Alexander J. R. Bishop Abstract Damage initiates a pleiotropic cellular response aimed at cellular survival when appropriate. To identify genes required for damage survival, we used a cell-based RNAi screen against the Drosophila genome and the alkylating agent methyl methanesulphonate (MMS). Similar studies performed in other model organisms report […]
New England Journal of Medicine: MicroRNA Expression, Survival, and Response to Interferon in Liver Cancer
October 8, 2009
Junfang Ji, PhD, Jiong Shi, MD, Anuradha Budhu, PhD, Zhipeng Yu, B.S., Marshonna Forgues, B.S., Stephanie Roessler, PhD, Stefan Ambs, PhD, M.P.H., Yidong Chen, PhD, Paul S. Meltzer, MD, Carlo M. Croce, MD, Lun-Xiu Qin, MD, PhD, Kwan Man, MD, PhD, Abstract BACKGROUND Hepatocellular carcinoma is a common and aggressive cancer that occurs mainly in men. We examined microRNA expression patterns, survival, and response to interferon […]
Cancer Research: Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers
July 1, 2009
Timothy R Rebbeck 1, Nandita Mitra, Susan M Domchek, Fei Wan, Shannon Chuai, Tara M Friebel, Saarene Panossian, Amanda Spurdle, Georgia Chenevix-Trench, kConFab; Christian F Singer, Georg Pfeiler, Susan L Neuhausen, Henry T Lynch, Judy E Garber, Jeffrey N Weitzel, Claudine Isaacs, Fergus Couch, Steven A Narod, Wendy S Rubinstein, Gail E Tomlinson, Patricia A Ganz, Olufunmilayo I Olopade, Nadine Tung, Joanne L Blum, Roger Greenberg, Katherine L Nathanson, Mary B Daly Abstract Inherited BRCA1/2 mutations confer elevated ovarian cancer risk. Knowledge of […]
Pediatric Blood & Cancer: Small cell undifferentiated variant of hepatoblastoma: adverse clinical and molecular features similar to rhabdoid tumors
March 1, 2009
Angela D Trobaugh-Lotrario 1, Gail E Tomlinson, Milton J Finegold, Lia Gore, James H Feusner Abstract Background: Small cell undifferentiated (SCU) histology in patients with stage I hepatoblastoma (HB) predicts an increased risk of relapse. We sought to determine the significance of SCU histology in patients with unresectable HB. Procedure: Patients enrolled in the pediatric Intergroup (INT0098) trial for HB and patients […]